This is a working overview of thymosin alpha 1, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-16. Anything still debated is marked as such rather than presented as settled.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
=== Gut microbiota === The effect of the low-FODMAP diet on the gut microbiota is not fully understood. It is thought that reduction of fermentable carbohydrates affects the composition and abundance of gut bacteria. FODMAPs are a main food source (prebiotic) for many gut bacteria. Deprived of this food source, there is less bacterial fermentation in the gut and less production of intestinal gas, which may also create conditions which favor certain species of bacteria and disfavor others. There is some evidence for negative effects of the low-FODMAP diet, such as reduction in the numbers of beneficial bacteria (e.g., Bifidobacteria). Such changes are comparable to dysbiosis. Other studies report no significant change in gut microbiota from the low-FODMAP diet. There is also some evidence for positive effects on the gut microbiota, such as improved microbial diversity and increased numbers of potentially beneficial bacterial species. The effect of the low-FODMAP diet on gut microbiota also seems to depend on the medical condition, with more profound changes in microbiota occurring in celiac disease or inflammatory bowel disease, but no significant microbiota changes occurring in IBS. Overall, the low-FODMAP diet may have a positive effect on the gut microbiota compared to normal diets. However, the evidence is mixed and there is significant study heterogeneity, probably because of variation in the methodology and length of the studies, and also differences in the studied populations such as genetics and baseline diet.
=== Tactics === Wenger was inspired by Borussia Mönchengladbach as a child, and was later influenced by Total Football, a playing style developed by Rinus Michels at Ajax in the 1970s. He recollected the team as having "perfect players everywhere and that was the sort of football I wanted to be playing myself". At Monaco, he employed a 4–4–2 formation, though he did trial 4–3–3, akin to Michels'. Wenger is an advocate of 4–4–2 as "no other formation is as efficient in covering space", but used it sparingly in his final seasons.
=== Dissolution and UN embargo === During the collapse of communism in Europe, Yugoslavia's republics introduced multiparty politics and held elections in 1990. During the same time, conflicts between the republics and the national communities intensified and federal institutions weakened. Just weeks after the first Croatian elections and after a Dinamo Zagreb-Red Star riot at the same stadium, at the Yugoslavia-Netherlands friendly in preparation for the 1990 World Cup, the Croatian crowd in Zagreb jeered the Yugoslav team and anthem and waved Dutch flags (owing to its resemblance to the Croatian tricolour). With the dissolution of Yugoslavia, the team split up and players joined the newly emerging national teams. The Belgrade-based team of the Federal Republic of Yugoslavia (FRY) was banned from competing at Euro 92 under UN sanctions. The decision was made on 31 May 1992, just 10 days before the competition commenced. The SFRY Yugoslav team had earned the top spot of their group during the disintegration, and the FRY team was unable to take its spot in the competition due to United Nations Security Council Resolution 757. Their place was taken by group runners-up Denmark, who went on to win the competition. After the breakup of Yugoslavia, Serbia and Montenegro proclaimed the state of FRY, which claimed to be the continuation of the previous Yugoslavia. A claim which was not generally accepted by the international community, except by FIFA and UEFA.
Sources: en.wikipedia.org
These hormones will cause the masculinization of the phenotypically indifferent organs. When exposed to testosterone, the genital tubercle elongates to form the penis. By fusion of the urogenital folds—elongated spindle-shaped structures that contribute to the formation of the urethral groove on the belly aspect of the genital tubercle—the urogenital sinus closes completely to form the spongy urethra and the labioscrotal swellings unite to form the scrotum. The secretion of testosterone during this phase plays a decisive role in the final shaping of the penis. After birth, testosterone levels drop significantly until puberty.
== Toxicity == Lectins are one of many toxic constituents of many raw plants that are inactivated by proper processing and preparation (e.g., cooking with heat, fermentation). For example, raw kidney beans naturally contain toxic levels of lectin (e.g. phytohaemagglutinin). Adverse effects may include nutritional deficiencies, and immune (allergic) reactions.
Electrical stimulation using implantable devices came into modern usage in the 1980s, and its techniques and applications have continued to develop and expand. These are methods where an operation is required to position an electrode. The stimulator, with the battery, similar to a pacemaker, may also be implanted, or may remain outside the body. In general, neuromodulation systems deliver electrical currents and typically consist of the following components: An epidural, subdural, or parenchymal electrode placed via minimally invasive needle techniques (so-called percutaneous leads) or an open surgical exposure to the target (surgical "paddle" or "grid" electrodes), or stereotactic implants for the central nervous system, and an implanted pulse generator (IPG). Depending on the distance from the electrode access point, an extension cable may also be added into the system. The IPG can have either a non-rechargeable battery needing replacement every 2–5 years (depending on stimulation parameters) or a rechargeable battery that is replenished via an external inductive charging system. Although most systems operate via delivery of a constant train of stimulation, there has recently been an emergence of so-called "feed-forward" stimulation, in which the device's activation is contingent on a physiological event, such as an epileptic seizure. In this circumstance, the device is activated and delivers a desynchronizing pulse to the cortical area that is undergoing an epileptic seizure.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.